170 related articles for article (PubMed ID: 31764435)
1. The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.
Hanna DL; Law SJ; Merrick SA; Heptinstall L; Bass P; Dupont P; Sheri A
Melanoma Res; 2020 Jun; 30(3):321-324. PubMed ID: 31764435
[TBL] [Abstract][Full Text] [Related]
2. Use of Ipilimumab and Pembrolizumab in Metastatic Melanoma in a Combined Heart and Kidney Transplant Recipient: A Case Report.
Soellradl I; Kehrer H; Cejka D
Transplant Proc; 2020 Mar; 52(2):657-659. PubMed ID: 32044081
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
4. Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy.
Sadaat M; Jang S
J Oncol Pract; 2018 Mar; 14(3):198-199. PubMed ID: 29257718
[No Abstract] [Full Text] [Related]
5. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.
Gambichler T; Hessam S; Lüttringhaus T; Boms S
Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
7. Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.
Deltombe C; Garandeau C; Renaudin K; Hourmant M
Transplantation; 2017 Sep; 101(9):e291. PubMed ID: 29633980
[No Abstract] [Full Text] [Related]
8. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy.
Padala SA; Patel SK; Vakiti A; Patel N; Gani I; Kapoor R; Muhammad S
J Oncol Pharm Pract; 2021 Mar; 27(2):470-476. PubMed ID: 32580640
[TBL] [Abstract][Full Text] [Related]
10. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients.
Venkatachalam K; Malone AF; Heady B; Santos RD; Alhamad T
Transplantation; 2020 May; 104(5):1041-1047. PubMed ID: 31415036
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.
Zehou O; Leibler C; Arnault JP; Sayegh J; Montaudié H; Rémy P; Glotz D; Cordonnier C; Martin L; Lebbé C
Am J Transplant; 2018 Dec; 18(12):3065-3071. PubMed ID: 30107088
[TBL] [Abstract][Full Text] [Related]
12. The transmission of donor-derived malignant melanoma to a renal allograft recipient.
Milton CA; Barbara J; Cooper J; Rao M; Russell C; Russ G
Clin Transplant; 2006; 20(5):547-50. PubMed ID: 16968479
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac Allograft.
Goodman AE; Karapetyan L; Pugliano-Mauro M; Levenson JE; Luke JJ
Front Immunol; 2021; 12():660795. PubMed ID: 33828564
[TBL] [Abstract][Full Text] [Related]
14. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
15. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
[No Abstract] [Full Text] [Related]
16. Acute renal transplant rejection following nivolumab therapy for metastatic melanoma.
Tan B; Baxter M; Casasola R
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33558380
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma.
Schvartsman G; Perez K; Sood G; Katkhuda R; Tawbi H
Ann Intern Med; 2017 Sep; 167(5):361-362. PubMed ID: 28761949
[No Abstract] [Full Text] [Related]
18. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP
Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170
[TBL] [Abstract][Full Text] [Related]
19. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
20. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
